ALS drug trial extended to check Long-Term safety
NCT ID NCT06903286
Summary
This study aimed to check the long-term safety of an oral medication called SPG302 for people with ALS (Lou Gehrig's disease). It was an extension of an earlier trial, allowing 16 participants to continue taking the drug for up to one year. The main goal was to monitor side effects while also tracking whether the drug helped slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5042, Australia
-
Macquarie University
North Ryde, New South Wales, 2109, Australia
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029, Australia
Conditions
Explore the condition pages connected to this study.